On assessing the presence of evaluation-time bias in progression-free survival in randomized trials

被引:5
|
作者
Kay, Richard [1 ]
Wu, Jane [2 ]
Wittes, Janet [3 ]
机构
[1] RK Stat Ltd, Great Longstone, England
[2] Genta Inc, Berkeley Hts, NJ USA
[3] Stat Collaborat, Washington, DC USA
关键词
progression-free survival; simulation; logrank test;
D O I
10.1002/pst.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluation (or assessment)-time bias can arise in oncology trials that study progression-free survival (PFS) when randomized groups have different patterns of timing of assessments. Modelling or computer simulation is sometimes used to explore the extent of such bias; valid results require building such simulations under realistic assumptions concerning the timing of assessments. This paper considers a trial that used a logrank test where computer simulations were based on unrealistic assumptions that severely overestimated the extent of potential bias. The paper shows that seemingly small differences in assumptions can lead to dramatic differences in the apparent operating characteristics of logrank tests. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [21] Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
    Matulonis, Ursula A.
    Oza, Amit M.
    Ho, Tony W.
    Ledermann, Jonathan A.
    CANCER, 2015, 121 (11) : 1737 - 1746
  • [22] Progression-free survival in oncology: Caveat emptor!
    Bergmann, Troels K.
    Christensen, Mette Marie H.
    Henriksen, Daniel P.
    Haastrup, Maija Bruun
    Damkier, Per
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (03) : 240 - 244
  • [23] Concordance index: Surrogacy of progression-free survival for overall survival
    Fan, Yiwei
    Yin, Guosheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [24] Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    CANCERS, 2021, 13 (01) : 1 - 14
  • [25] The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration
    Jamoul, Corinne
    Collette, Laurence
    Coart, Elisabeth
    D'Hollander, Koenraad
    Burzykowski, Tomasz
    Saad, Everardo D.
    Buyse, Marc
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [26] The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration
    Corinne Jamoul
    Laurence Collette
    Elisabeth Coart
    Koenraad D’Hollander
    Tomasz Burzykowski
    Everardo D. Saad
    Marc Buyse
    BMC Medical Research Methodology, 22
  • [27] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Petrelli, Fausto
    Coinu, Andrea
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (02) : 124 - 131
  • [28] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Fausto Petrelli
    Andrea Coinu
    Karen Borgonovo
    Mary Cabiddu
    Sandro Barni
    Hepatobiliary&PancreaticDiseasesInternational, 2015, 14 (02) : 124 - 131
  • [29] 2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years
    Parish, Austin J.
    Cristea, Ioana Alina
    Schuit, Ewoud
    Ioannidis, John P. A.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 150 : 106 - 115
  • [30] A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer
    Tanase, Takanori
    Hamada, Chikuma
    Yoshino, Takayuki
    Ohtsu, Atsushi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5851 - 5855